|
市場調査レポート
商品コード
1064097
がん免疫療法の世界市場:用途別、エンドユーザー別、地域別分析-予測(~2028年)Cancer Immunotherapy Market Forecasts to 2028 - Global Analysis By Application (Blood Cancers, Ovarian Cancer, Pancreatic Cancer, Liver Cancer), End User (Hospitals & Clinics, Ambulatory Surgical Centres) and By Geography |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。 |
がん免疫療法の世界市場:用途別、エンドユーザー別、地域別分析-予測(~2028年) |
出版日: 2022年02月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
|
世界のがん免疫療法の市場規模は、2021年に1,193億9,000万米ドルとなり、2028年には3,374億2,000万米ドルに達し、予測期間中のCAGRは16.0%となる見込みです。
当レポートでは、世界のがん免疫療法市場について調査分析し、促進要因、抑制要因、製品・用途・エンドユーザー・地域別市場分析、企業プロファイルを提供しています。
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
According to Stratistics MRC, the Global Cancer Immunotherapy Market is accounted for $119.39 billion in 2021 and is expected to reach $337.42 billion by 2028 growing at a CAGR of 16.0% during the forecast period. Cancer immunotherapy is a cancer treatment that enhances the immune system's ability to fight cancer. This therapy is preferable than the old technique because it provides long-term cancer protection, has less side effects, and treats a wider range of cancers.
Market Dynamics:
Driver:
Growing adoption of immunotherapy
The treatment options for cancer, such as chemotherapies and radiation therapy, although have more side effects, are more widely used as compared to immunotherapies. While they can effectively kill or remove cancer cells, the use of these treatments is often limited because they tend to destroy healthy cells in large numbers as well. As immunotherapies involve the mechanism of enhancing the body's own immunity using man-made proteins such as monoclonal antibodies, they are accepted worldwide over other treatment options.
Restraint:
High product developmental cost
The cost of developing new products for cancer immunotherapy is on the higher side. Due to this, there is a negative impact on the growth of the market.
Opportunity:
Technological developments
The developments in technology and surge in healthcare expenditure positively affect the cancer immunotherapy market. Furthermore, increase in clinical trials against several types of cancers in immunotherapy extends profitable opportunities to the market players in the forecast period.
Threat:
Stringent government regulations
The stringent regulations related to cancer immunotherapy are anticipated to be a major threat for the growth of the cancer immunotherapy market. Government have better supervision over the use of immunotherapy and is also taking care of the clinical trials going on user the government norms, which has made it difficult to the companies to enter the industry and is hence expected to hinder the growth of the market.
The hospitals & clinics segment is expected to be the largest during the forecast period
Hospitals and clinics remain the most favoured medical settings, as these institutions are equipped with advanced facilities to allow for effective diagnosis and treatment. High adoption of advanced diagnostics and treatment equipment, as well as therapeutics, supported by public and private funding, further improves the healthcare quality offered by hospitals. Relatively short wait times and ease of getting appointments are projected to widen the patient base opting for clinic-based healthcare. Progressive growth in the demand for quality cancer therapeutics in clinics is influencing clinicians to focus on offering cancer immunotherapy to patients, which is driving the exponential adoption of cancer therapeutics in clinics.
The monoclonal antibodies segment is expected to have the highest CAGR during the forecast period
Monoclonal antibody based drugs assist in flagging cancer cells, trigger cell-membrane destruction, inhibiting malignant cell proliferation, preventing blood vessel growth, easy chemotherapy delivery and binding cancer and immune cells among other benefits. Their ability to trigger an antitumor immune response makes them highly sought after.
Region with largest share:
North America is projected to hold the largest market share owing to the favourable dynamics, such as progressive improvements in healthcare infrastructure and government initiatives underpinning the R&D activities of players. The rising number of patients suffering from cancer, increasing adoption rate of immunotherapy, and development of bioinformatics tools are enhancing the drug development process also contribute towards the market growth.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR due to the increasing ageing population, altering lifestyles and socio-economic changes. Consequently, healthcare spending to develop advanced research & development facilities for designing high-grade oncology diagnostics are taking place, a factor which is expected to fuel cancer immunotherapy market growth.
Key players in the market
Some of the key players profiled in the Cancer Immunotherapy Market include Merck & Co., Inc., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Bristol-Myers Squibb, ELI Lilly and Company, Dr. Reddy's Laboratories Ltd, Astrazeneca, Amgen Inc., Lupin Limited, Bausch Health Companies Inc., Celgene Corporation, Apotex Inc, Immunomedics Inc, and Hikma Pharmaceutical PLC.
Key developments:
In September 2021: Amgen Plc. announced its first combination study results from its Phase 1b/2 CodeBreaK 101 study, a comprehensive global clinical development program in patients with KRAS G12C-mutated advanced colorectal cancer. It shows that combining LUMAKRASTM (sotorasib) with Vectibix® (panitumumab) demonstrate efficacy and safety.
In September 2021: Bristol-Myers Squibb Company conducted a survey that included 250 oncologists, surgeons and specialists from countries like U.S., Germany and Japan. The survey revealed the potential immunotherapy carries for cancers that are detected at an early stage.
Products Covered:
Applications Covered:
End Users Covered:
Regions Covered:
What our report offers:
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options: